AGREEMENT THIS AGREEMENT, effective November 2, 2000, is entered intoAgreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Manitoba
MASTER SERVICES AGREEMENTMaster Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
This Master Services Agreement ("Agreement") is entered into as of May 17th, 2007 (the "Effective Date") by and between YM Biosciences Inc., a Canadian corporation with an office at 5045 Orbitor Drive, Bldg. 11, Suite 400, Mississauga, Ontario L4W 4Y4 (collectively with its Affiliates hereinafter the "YMB") and Allphase Clinical Research Services Inc., having offices at 19 Camelot Drive, Ottawa, Ontario, K2G 5W6 (collectively with its Affiliates hereinafter "ALLPHASE"). YMB and ALLPHASE are referred to singly as "Party" and jointly as "Parties" throughout this Agreement.
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD. YB1002-203TaxotereClinical Research Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
This Clinical Research Services Agreement (this Agreement) is made and entered into effective as of 10 December 2004 (the “Effective Date”), by and between YM BIOSCIENCES, INC. (hereafter “YM”), a Canadian corporation, with its principal office at 5045 Orbitor Drive, Building 11, Suite 400, Mississauga, Ontario L4W 4Y4, Canada, and PHARM-OLAM INTERNATIONAL Ltd. (hereafter “POI”), a Texas limited partnership, with its principal office at 450 N Sam Houston Parkway, Suite 250, Houston, TX 77060, United States.
and License Agreement Relating to Nimotuzumab (TheraCIM h-R3)License Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
Work Order #1 Dated November 9, 2007Ym Biosciences Inc • March 4th, 2010 • Pharmaceutical preparations
The services described herein will be provided in accordance with the terms and conditions of the Master Services Agreement, dated August 24, 2007, between AAIPharma Inc., on behalf of itself and its subsidiaries (collectively, ‘AAIPharma’) and YM Biosciences USA Inc. (hereinafter referred to as “YMB USA”).
MASTER SERVICES AGREEMENTMaster Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations
This Master Services Agreement ("Agreement") is entered into as of August 24th, 2007 (the "Effective Date") by and between YM Biosciences USA Inc., a corporation incorporated in Delaware located at 701 Lee Road, Suite 201, Wayne, PA 19087 (hereinafter “YMB USA USA”) and AAIPharma Inc., having offices at 2320 Scientific Drive, Wilmington, North Carolina 28405, including its subsidiaries (“AAIPharma”). YMB USA USA and AAIPharma are referred to singly as "Party" and jointly as "Parties" throughout this Agreement.
ContractDevelopment and Licence Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
And Development and License Agreement Relating to Nimotuzumab (TheraCIM h-R3)Development and License Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
ContractDevelopment and License Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
Joint Venture Shareholders' Agreement November 14, 1995Shareholders' Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations
Between: York Medical Inc. ("YM”), a company incorporated under the laws of the Province of Ontario, Canada, CIMYh4 INC., a company incorporated under the laws of the Province of Ontario, Canada ("CIMYM;'), and CIMAB S.A., ("CIMAB") a Cuban company incorporated under the laws of the Republic of Cuba, representing Centro de Inmunologia Molecular (“CIM”).
